Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Dexpanthenol foam spray, new formulation
Dexpanthenol foam, new formulation · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Arm 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Dexpanthenol foam spray, new formulation | DRUG | 2 applications of 2 micro liter/square centimeter on a 4X4 cm area corresponding to 32 micro liter |
| Dexpanthenol foam spray, old formulation | DRUG | 2 applications of 2 micro liter/square centimeter on a 4X4 cm area corresponding to 32 micro liter |
Inclusion Criteria: * Healthy subjects * Phototype: I to IV according to Fitzpatrick scale Exclusion Criteria: * Pregnant or nursing women * Subjects registered as being in exclusion period in the French Health Minister file of subjects * Subjects with known allergy to cosmetics, skin care produc...
Top 20 of 31 competitors
Dexpanthenol foam, new formulation is a small molecule dermatology product developed by Bayer AG. It is being studied in Phase 2 clinical trials for erythema and skin abnormalities. The formulation is applied as a foam and has been evaluated in two completed Phase 2 trials conducted in France.
Dexpanthenol foam, new formulation is being developed for erythema, which is skin redness, and for skin abnormalities. The clinical program has focused on these dermatological conditions. One trial examined its efficacy in thermic erythema, while another assessed the moisturizing effect of two dexpanthenol formulations.
Bayer AG is the developer of dexpanthenol foam, new formulation. Bayer AG trades on the OTC market under the ticker BAYRY. The company is responsible for the clinical development of this dermatology asset.
Dexpanthenol foam, new formulation is in Phase 2 clinical development. Two Phase 2 trials have been completed, and no active trials are currently listed. The drug is investigational and has not been approved by the FDA for any indication.
Dexpanthenol foam, new formulation has been studied in two completed Phase 2 trials. NCT00839462 evaluated its efficacy in thermic erythema with 55 participants in France. NCT00839280 assessed the moisturizing effect of two dexpanthenol formulations with 19 participants, also in France. Both trials enrolled healthy volunteers.
Yes, dexpanthenol foam, new formulation is also known as dexpanthenol foam spray, new formulation. These names refer to the same Bayer AG product candidate being studied for erythema and skin abnormalities in Phase 2 trials.